Literature DB >> 27237421

Analysis of Clinical Features and Outcomes of Skull Base Chordoma in Different Age-Groups.

Kaibing Tian1, Liang Wang2, Ke Wang1, Junpeng Ma1, Da Li1, Shuyu Hao1, Yang Yang1, Jiang Du3, Guijun Jia4, Liwei Zhang1, Zhen Wu1, Junting Zhang5.   

Abstract

OBJECTIVE: The objective of the current study was to compare the clinical features and outcomes between younger and older patients with skull base chordoma (SBC).
METHODS: In this retrospective study, patients with SBC who underwent surgical treatment between February 2005 and December 2014 were included. Clinical features were recorded, including the signal intensity ratio of tumor to brain stem in T1 (RT1), T2 (RT2), and enhanced T1 (REN) sequences in primary patients with complete preoperative magnetic resonance images. The clinical features and outcomes were compared between younger (≤24 years) and older patients (≥25 years).
RESULTS: In the present study, 238 patients were included. Younger patients experience more aggressive resection than do older patients (P = 0.045), and the SBCs of younger patients tended to be located in the occipitocervical region compared with older patients (P = 0.007). REN value in the younger group was lower than in the older group (P = 0.014), and the value of RT2 was higher in younger patients than in older patients (P = 0.015). The risk of progression was higher in older patients compared with younger patients (P = 0.030); the risk of having a poor neurologic status in older patients was higher than in younger patients (P = 0.044).
CONCLUSIONS: In younger patients, there were more SBCs located in the occipitocervical regions, and younger patients tended to undergo more aggressive resection. The tumor signal intensity of younger patients with SBC was higher in T2 images but lower in enhanced T1 images. A younger age was a favorable factor for a longer progression-free survival and a good neurologic status at follow-up.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Age; Clinical feature; Outcome; Skull base chordoma

Mesh:

Year:  2016        PMID: 27237421     DOI: 10.1016/j.wneu.2016.05.035

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  MR Imaging Grading System for Skull Base Chordoma.

Authors:  K Tian; L Wang; J Ma; K Wang; D Li; J Du; G Jia; Z Wu; J Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

2.  MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.

Authors:  J Bai; J Shi; S Zhang; C Zhang; Y Zhai; S Wang; M Li; C Li; P Zhao; S Geng; S Gui; L Jing; Y Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-07       Impact factor: 3.825

3.  Peri-operative prognostic factors for primary skull base chordomas: results from a single-center cohort.

Authors:  Emanuele La Corte; Morgan Broggi; Alberto Raggi; Silvia Schiavolin; Francesco Acerbi; Giovanni Danesi; Mariangela Farinotti; Giovanni Felisati; Alberto Maccari; Bianca Pollo; Marco Saini; Claudia Toppo; Francesca Valvo; Riccardo Ghidoni; Maria Grazia Bruzzone; Francesco DiMeco; Paolo Ferroli
Journal:  Acta Neurochir (Wien)       Date:  2020-01-16       Impact factor: 2.216

4.  Dosimetric advantages of proton beam therapy compared to intensity-modulated radiation therapy for retroperitoneal chordoma.

Authors:  Nathan Y Yu; Sujay A Vora
Journal:  Rare Tumors       Date:  2019-09-23

5.  Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.

Authors:  Jiwei Bai; Mingxuan Li; Jianxin Shi; Liwei Jing; Yixuan Zhai; Shuheng Zhang; Junmei Wang; Peng Zhao; Chuzhong Li; Songbai Gui; Yazhuo Zhang
Journal:  Neurosurg Rev       Date:  2021-10-08       Impact factor: 3.042

6.  Application of nomograms to predict overall and cancer-specific survival in patients with chordoma.

Authors:  Weipeng Zheng; Yuanping Huang; Tianwang Guan; Songfang Lu; Liquan Yao; Senrui Wu; Haoyi Chen; Ning Wang; YingJie Liang; Wende Xiao; Xin Jiang; Shifeng Wen
Journal:  J Bone Oncol       Date:  2019-06-24       Impact factor: 4.072

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.